Indivior PLC (INDV)
32.97
-0.57 (-1.70%)
Inactive · Last trade price on Jan 23, 2026
Indivior Employees
Indivior had 1,000 employees as of June 30, 2025. The number of employees did not change compared to the same quarter last year.
Employees
1,000
Change
n/a
Growth
n/a
Revenue / Employee
$1,180,000
Profits / Employee
$124,000
Market Cap
4.12B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 1,000 | 0 | - | 1,000 | 0 |
| Dec 31, 2024 | 1,051 | -113 | -9.71% | 1,030 | 21 |
| Sep 30, 2024 | 1,000 | 0 | - | 1,000 | 0 |
| Jun 30, 2024 | 1,000 | 0 | - | 1,000 | 0 |
| Mar 31, 2024 | 1,000 | 0 | - | 1,000 | 0 |
| Dec 31, 2023 | 1,164 | 236 | 25.43% | 1,164 | 0 |
| Sep 30, 2023 | 1,000 | 100 | 11.11% | 1,000 | 0 |
| Jun 30, 2023 | 1,000 | 100 | 11.11% | 1,000 | 0 |
| Mar 31, 2023 | 1,000 | 200 | 25.00% | 1,000 | 0 |
| Dec 31, 2022 | 928 | 43 | 4.86% | 928 | 0 |
| Sep 30, 2022 | 900 | 100 | 12.50% | 900 | 0 |
| Jun 30, 2022 | 900 | 100 | 12.50% | 900 | 0 |
| Mar 31, 2022 | 800 | 12 | 1.52% | 800 | 0 |
| Dec 31, 2021 | 885 | 97 | 12.31% | 885 | 0 |
| Sep 30, 2021 | 800 | 12 | 1.52% | 800 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
INDV News
- 1 day ago - Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance - GlobeNewsWire
- 7 days ago - Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder - GlobeNewsWire
- 15 days ago - Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse - GlobeNewsWire
- 22 days ago - Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th - GlobeNewsWire
- 4 weeks ago - New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities - GlobeNewsWire
- 6 weeks ago - National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder - GlobeNewsWire
- 7 weeks ago - Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering - GlobeNewsWire
- 7 weeks ago - Indivior Announces Proposed Convertible Senior Notes Offering - GlobeNewsWire